Survival benefit from RectroNectin-activated cytokine-induced killer cells combined with chemotherapy in advanced EGFR wild-type lung adenocarcinoma

Immunotherapy. 2018 Mar 1;10(6):501-510. doi: 10.2217/imt-2017-0140.

Abstract

Aim: To investigate the efficacy of chemotherapy and RectroNectin-activated cytokine-induced killer (R-CIK) cell immunotherapy in patients with advanced EGFR wild-type lung adenocarcinoma.

Methods: Using data gathered from a single institution, 125 patients with stage IIIB or IV EGFR wild-type lung adenocarcinoma between January 2009 and June 2015 were identified and enrolled in this retrospective study.

Results: The disease control rates and median overall survival was better in R-CIK group compared with control group. Multivariate survival analysis showed that R-CIK cell treatment was an independent prognostic factor for overall survival.

Conclusion: R-CIK cell immunotherapy may prolong survival of patients with advanced EGFR wild-type lung adenocarcinoma.

Trial registration: ClinicalTrials.gov NCT02621333.

Keywords: EGFR; chemotherapy; immunotherapy; lung cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / mortality
  • Adenocarcinoma / therapy*
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cells, Cultured
  • Combined Modality Therapy
  • Cytokine-Induced Killer Cells / immunology
  • Cytokine-Induced Killer Cells / transplantation*
  • Female
  • Fibronectins / metabolism
  • Follow-Up Studies
  • Genes, erbB-1
  • Humans
  • Immunotherapy, Adoptive / methods*
  • Lung Neoplasms / mortality
  • Lung Neoplasms / therapy*
  • Male
  • Neoplasm Staging
  • Recombinant Proteins / metabolism
  • Retrospective Studies
  • Survival Analysis
  • Treatment Outcome

Substances

  • Fibronectins
  • Recombinant Proteins
  • retronectin

Associated data

  • ClinicalTrials.gov/NCT02621333